Bfsg, LLC Phathom Pharmaceuticals, Inc. Transaction History
Bfsg, LLC
- $838 Million
- Q4 2024
A detailed history of Bfsg, LLC transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Bfsg, LLC holds 300 shares of PHAT stock, worth $1,689. This represents 0.0% of its overall portfolio holdings.
Number of Shares
300
Previous 300
-0.0%
Holding current value
$1,689
Previous $5,000
60.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding PHAT
# of Institutions
142Shares Held
74.8MCall Options Held
42.3KPut Options Held
45.7K-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.1MShares$56.9 Million9.84% of portfolio
-
Medicxi Ventures Management (Jersey) LTD7.46MShares$42 Million13.31% of portfolio
-
Jennison Associates LLC7.06MShares$39.8 Million0.04% of portfolio
-
Invesco Ltd. Atlanta, GA4.1MShares$23.1 Million0.01% of portfolio
-
Carlyle Group Inc. Washington, DC3.5MShares$19.7 Million9.52% of portfolio
About Phathom Pharmaceuticals, Inc.
- Ticker PHAT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,175,200
- Market Cap $221M
- Description
- Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...